Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
about
Implications of mismatch repair-deficient status on management of early stage colorectal cancerStandard chemotherapy with cetuximab for treatment of colorectal cancerOverall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysisAdjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO.A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markersCombination Adjuvant Chemotherapy with Targeted Drugs for Treatment of Colorectal Cancer: A Network Meta-Analysis.Impact of venous invasion on the efficacy of adjuvant chemotherapy in elderly patients with stage III colorectal cancer.Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab).Therapeutic strategies against cancer stem cells in human colorectal cancer.Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.
P2860
Q26772272-BCB6A3D5-58DD-4809-A18D-481B52F7868FQ28088693-78E44B7E-E470-4A9A-8169-D96A7F5210F3Q30235144-6001D94B-5D21-44C7-AA02-A0D1298F6AEAQ33576805-4B756D37-9776-4EB2-89DB-86737EEC26FAQ34537664-4F1EA5FD-D763-4345-832D-977B8E3FF2FFQ36429095-9E368D99-87C0-49BB-BE1F-0409CBAD9EC4Q37413869-AEA0665C-FD9E-4C08-95B7-29B39CB0CD22Q38644154-CE6E45BF-594A-4D67-B6CD-0A7E9E2ED8F2Q38683073-65C0B00A-9A96-418C-AE81-A08C0C09B6D1Q38906609-DF9F4121-02ED-4A88-9934-966828B4AD0AQ47149854-FC325C80-5523-4F62-BF98-6F2F61614FC7Q48226075-7D0E3F78-ABBE-4093-B56C-8AA45F4CB7D7
P2860
Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Comparison of FOLFIRI with or ...... iance) intergroup trial N0147.
@ast
Comparison of FOLFIRI with or ...... iance) intergroup trial N0147.
@en
type
label
Comparison of FOLFIRI with or ...... iance) intergroup trial N0147.
@ast
Comparison of FOLFIRI with or ...... iance) intergroup trial N0147.
@en
prefLabel
Comparison of FOLFIRI with or ...... iance) intergroup trial N0147.
@ast
Comparison of FOLFIRI with or ...... iance) intergroup trial N0147.
@en
P2093
P2860
P1476
Comparison of FOLFIRI with or ...... iance) intergroup trial N0147.
@en
P2093
Alliance for Clinical Trials in Oncology
Anthony F Shields
Axel Grothey
Barbara A Pockaj
Emily Chan
Frank A Sinicrope
Garth D Nelson
Gist H Farr
James T Quesenberry
Jeffrey L Berenberg
P2860
P304
P356
10.1016/J.CLCC.2013.12.002
P407
P577
2013-12-28T00:00:00Z